Recent Quotes (30 days)

You have no recent quotes
chg | %

AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for AEZS
1.13
+0.06 (5.61%)
After Hours: 1.15 +0.02 (1.77%)
Oct 20, 5:45PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.06 - 1.14
52 week 0.82 - 1.74
Open 1.06
Vol / Avg. 550,027.00/1.17M
Mkt cap 62.24M
P/E     -
Div/yield     -
EPS -0.61
Shares 57.89M
Beta 1.51
Inst. own 31%
Sep 9, 2014
AEterna Zentaris Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2014
AEterna Zentaris Inc at Canaccord Genuity Growth Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -441.13%
Operating margin - -444.96%
EBITD margin - -404.53%
Return on average assets -36.37% -42.94%
Return on average equity -157.85% -525.41%
Employees 76 -
CDP Score - -

Address

1405 du Parc-Technologique Blvd.
QUEBEC, QC G1P 4P5
Canada
+1-418-6528525 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company�s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Richard Sachse M.D., Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Philip A. Theodore Senior Vice President, Chief Administrative Officer, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Amelie Metivier Assistant Secretary
Bio & Compensation  - Reuters
Juergen H. L. Ernst Lead Director
Age: 75
Bio & Compensation  - Reuters
M. Marcel Aubut QC Independent Director
Bio & Compensation  - Reuters
Jose P. Dorais Independent Director
Bio & Compensation  - Reuters
Carolyn Egbert Independent Director
Bio & Compensation  - Reuters